Nitric Oxide

證據等級: L5

預測適應症: 10 個

Nitric Oxide: From Pulmonary Hypertension to Malformation Syndrome with Periodontal Component

One-Sentence Summary

Nitric Oxide (inhaled; DB00435) is an endogenous gaseous signaling molecule with established clinical use for managing pulmonary hypertension in other global markets (e.g., FDA-approved for neonatal persistent pulmonary hypertension); it currently has no registered product authorizations in India. The TxGNN model predicts it may be effective for malformation syndrome with odontal and/or periodontal component, with 0 clinical trials and 20 general periodontitis publications retrieved — none of which specifically address this rare congenital syndrome in the context of nitric oxide therapy.

Quick Overview

Item	Content
Original Indication	Pulmonary hypertension (reference use in other markets; no India registration)
Predicted New Indication	Malformation syndrome with odontal and/or periodontal component
TxGNN Prediction Score	99.57%
Evidence Level	L5
India Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, Nitric Oxide is an endogenous gaseous molecule produced by nitric oxide synthase (NOS) enzymes. Its primary pharmacological actions include selective pulmonary vasodilation via the cyclic GMP (cGMP) second-messenger pathway, immune modulation through inducible NOS (iNOS) in inflamed tissue, and antimicrobial activity via reactive nitrogen species (RNS).

The potential mechanistic connection to periodontal disease rests on two indirect observations: (1) RNS generated by NO can suppress periodontal pathogens, and (2) iNOS-mediated NO production is elevated in inflamed gingival tissue, suggesting a role in local innate immune regulation. These observations form the knowledge-graph basis for the TxGNN prediction — specifically, the proximity of NO pathway nodes to periodontitis and diabetes metabolic clusters.

However, the specifically predicted condition — malformation syndrome with odontal and/or periodontal component — is a rare congenital syndrome characterized by structural abnormalities of teeth and periodontal attachment, not routine acquired periodontitis. There are no disease-specific mechanistic studies, no clinical trials, and no case reports linking NO therapy to this syndrome. The high TxGNN score most likely reflects knowledge-graph topology rather than a validated therapeutic relationship, and should be interpreted with caution.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

All 20 retrieved publications address general periodontitis; none specifically investigates NO therapy for the predicted congenital syndrome. Listed below for contextual reference only.

PMID	Year	Type	Journal	Key Findings
35688447	2022	Clinical Practice Guideline	J Clin Periodontol	EFP S3-level CPG for Stage IV periodontitis; evidence-based recommendations for complex attachment-loss cases including tooth flaring, bite collapse
22057194	2012	Review	Diabetologia	Bidirectional periodontitis–diabetes relationship; ~3× elevated periodontitis risk in diabetic patients, with potential for glycaemic impact
35420698	2022	Cochrane Review	Cochrane Database Syst Rev	Subgingival instrumentation for glycaemic control in diabetes; systematic review of bidirectional relationship
38907216	2024	Review	J Nanobiotechnol	Biomaterial-mediated macrophage immunotherapy for periodontitis; immunomodulatory drug delivery approaches
29291254	2018	Cochrane Review	Cochrane Database Syst Rev	Supportive periodontal therapy (SPT) effectiveness for maintaining teeth after active periodontal treatment
38362600	2024	Clinical Study	J Dent Res	Oral–gut microbial dysbiosis in Stage III/IV periodontitis (n=47); longitudinal effect of periodontal treatment on microbiome
36883660	2023	Review	J Dent Res	Gingival fibroblasts as innate immune sentinel cells; role in responding to bacterial invasion and modulating periodontal inflammation
9495612	1998	Observational	J Clin Periodontol	Subgingival microbial complexes characterized in 185 subjects; foundational microbiology study identifying orange/red complex pathogens
20599785	2010	Review	Biochem Pharmacol	Complement system overactivation in periodontal inflammation; systemic impact of periodontal disease
18673013	2008	Review	J Periodontol	Biologic systems model integrating host genetics, microbial composition, systemic immune response, and gingival inflammatory mediators

India Market Information

Nitric Oxide (DB00435) currently has no registered product authorizations in India. No marketing licenses are on file with CDSCO.

Safety Considerations

Drug Interactions: 61 total interactions identified (DDInter database). Clinically significant interactions:

Interacting Drug	Severity	Clinical Note
Nitrous acid	Major	Additive reactive nitrogen species formation; avoid concurrent use
Tetracaine (ophthalmic)	Moderate	Risk of methemoglobinemia with topical anesthetics; monitor methemoglobin levels
Lidocaine (topical)	Moderate	Risk of methemoglobinemia; monitor methemoglobin levels
Benzocaine (topical)	Moderate	Risk of methemoglobinemia; monitor methemoglobin levels

57 additional interactions were classified as Unknown severity, including Morphine, Omeprazole, Vancomycin, Epinephrine, Heparin, Dexamethasone, Epoprostenol, and others. Formal warnings and contraindications data are not available for the India market; please refer to the applicable package insert.

Conclusion and Next Steps

Decision: Hold

Rationale: Despite a high TxGNN score (99.57%), this prediction has no supporting clinical trials and no disease-specific literature. All 20 retrieved publications relate to general periodontitis, not the specifically predicted rare congenital syndrome. Evidence level L5 indicates this is a model prediction with no actual studies supporting this repurposing direction; advancing without further validation would not be scientifically justified.

To proceed, the following is needed:

Basic research establishing a mechanistic link between NO signaling and the specific pathophysiology of this congenital odontal/periodontal malformation syndrome
Targeted literature search focused on the genetic and developmental etiology of the syndrome and any documented NO-related dysregulation
Case reports or observational data in patients carrying this specific diagnosis
Mechanism of action data from DrugBank (DG002 remediation: query DrugBank API)
India regulatory safety data — package insert warnings and contraindications (DG001 remediation: download CDSCO/TFDA PDF and parse)

Note: Among all 10 predicted indications in this evidence pack, pulmonary arterial hypertension (rank 7, L2 evidence, “Proceed with Guardrails”) and PAH associated with congenital heart disease (rank 8, L2 evidence, “Proceed with Guardrails”) carry substantially stronger clinical evidence and a more direct mechanistic rationale for inhaled NO. If resources are limited, those indications represent higher-priority candidates for further evaluation.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.